louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03023956: Outcome of Proximal Humerus Fractures :Anatomic Neck Fractures vs Surgical Neck Fractures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Humeral Fracture, Proximal
Internal Fixation; Complications, Mechanical, Bones of Limb
Lead sponsor: Zhoupu Hospital, Pudong New Area, Shanghai, China
Sponsor class: OTHER
First posted: 2017-01-18
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: From May ,2013 to April 2015, patients with fractures of the proximal humerus who were treated with locking plate.

Brief summary: From April ,2014 to April 2015,31 patients with fractures of the proximal humerus were treated in our hospital. According to anatomic neck fractures (ANF) and surgical neck fractures (SNF), we divided the patients into two groups. All the patients were followed at least 1 year.


Eligibility criteria: Inclusion Criteria:

-From May ,2013 to April 2015, patients with fractures of the proximal humerus who were treated with locking plate.

Exclusion Criteria:

* Patients had pathologic fractures,
* Patients had previous surgery on the affected shoulder,
* Patients were treated with shoulder arthroplasty.
* Patients were treated with intramedullary nail.

Primary outcomes:
measure: change of head-shaft angle at 12months from 6months in two groups
timeFrame: 12months
Secondary outcomes:
measure: change of Offset at 12months from 6months in two groups
timeFrame: 12 months
measure: Constant-Murly scores at 3 months, 12 months and last follow-up
timeFrame: 3 months,12 months,last follow-up (last follow-up means recent evaluation before database lock, it is more than 12months )
measure: change of the distance between the screw tip and the subchondral surface(TSD) at 12months from 6months in two groups
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02467556: Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome
Official title: Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: CRPS
Keywords: CRPS
intervention
multimodal
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2015-06-10
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A ten week open label study intervention to evaluate the outcome for a psychological intervention combined with physiotherapy and medication with memantine-morphine in 10 CRPS patients.

Detailed description: Ten CRPS I patients attended an intervention for 10 weeks. First, the medication was started with morphine 10mg adding gradually to 30 mg per day. Then, in addition to morphine, memantine 5 mg was started adding the dose gradually up to 40 mg per day if tolerated. Physiotherapy and psychological intervention were mostly carried out in a weekly group gathering with home exercises that were recorded to a diary. Psychological and physiotherapy interventions lasted for eight weeks. A neurological examination was done before and after the intervention as well as a separate physiotherapist examination of the hands. Patients filled out questionnaires of mood, quality of life, pain, and CRPS descriptions before and after the intervention.

Eligibility criteria: Inclusion Criteria:

* CRPS type 1 for at least 6 months,
* pain NRS 4 or more

Exclusion Criteria:

* major psychiatric or neurological disease

Primary outcomes:
measure: Direction of change in patient reported CRPS symptom discriptors
timeFrame: Three months
Secondary outcomes:
measure: Direction of change in motor parameters
timeFrame: Three months
measure: Direction of change in psychological parameters
timeFrame: Three months
measure: Direction of change in quality of life
timeFrame: Three months
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital
state: HUS
Study officials:
affiliation: Professor
name: Eija Kalso, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Bean DJ, Johnson MH, Kydd RR. The outcome of complex regional pain syndrome type 1: a systematic review. J Pain. 2014 Jul;15(7):677-90. doi: 10.1016/j.jpain.2014.01.500. Epub 2014 Feb 12.
citation: Gustin SM, Schwarz A, Birbaumer N, Sines N, Schmidt AC, Veit R, Larbig W, Flor H, Lotze M. NMDA-receptor antagonist and morphine decrease CRPS-pain and cerebral pain representation. Pain. 2010 Oct;151(1):69-76. doi: 10.1016/j.pain.2010.06.022. Epub 2010 Jul 13.
citation: Elomaa M, Hotta J, de C Williams AC, Forss N, Ayrapaa A, Kalso E, Harno H. Symptom reduction and improved function in chronic CRPS type 1 after 12-week integrated, interdisciplinary therapy. Scand J Pain. 2019 Apr 24;19(2):257-270. doi: 10.1515/sjpain-2018-0098.
Clinical trial NCT03363256: Web-based Addiction Treatment: Cultural Adaptation With American Indians
Official title: Web-based Addiction Treatment: Cultural Adaptation With American Indians
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Substance Use Disorders
Keywords: Digital therapeutics
Adaptation
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2017-12-06
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the current study is to evaluate the preliminary efficacy of the Therapeutic Education System-Native Version (TES-NAV) (an efficacious web-delivered psychosocial intervention for substance use disorders adapted with American Indians/Alaska Natives \[AI/AN\]) to determine whether a future large-scale effectiveness trial is warranted. Specifically, a randomized controlled trial among urban AI/AN (N=80) attending outpatient addiction treatment services will be conducted to (1) estimate preliminary effect size of 12 weeks of TES-NAV on substance use disorder outcomes; (2) explore relevant moderators of TES-NAV outcomes; and (3) assess cultural factors that may correspond to variation in outcome.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Identify as American Indian or Alaska Native
* Recent alcohol or drug use
* Within first 30 days of current outpatient treatment episode

Exclusion Criteria:

* Planned treatment episode of less than 3 months
* Insufficient ability to provide informed consent

Primary outcomes:
measure: Consecutive weeks of drug/alcohol abstinence
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Native American Rehabilitation Association of the Northwest, Inc.
state: Oregon
Study officials:
References:
citation: Campbell AN, Turrigiano E, Moore M, Miele GM, Rieckmann T, Hu MC, Kropp F, Ringor-Carty R, Nunes EV. Acceptability of a web-based community reinforcement approach for substance use disorders with treatment-seeking American Indians/Alaska Natives. Community Ment Health J. 2015 May;51(4):393-403. doi: 10.1007/s10597-014-9764-1. Epub 2014 Jul 15.
citation: Campbell AN, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, Turrigiano E, Walters S, McClure EA, Kyle TL, Wahle A, Van Veldhuisen P, Goldman B, Babcock D, Stabile PQ, Winhusen T, Ghitza UE. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014 Jun;171(6):683-90. doi: 10.1176/appi.ajp.2014.13081055.
Clinical trial NCT06925256: Considering Peripheral Nerve Injury, Is It Safe to Perform Transradial Angiography?
Official title: Considerin Peripheral Nerve Injury, Is It Safe to Perform Transradial Angiography?
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Neuropathic Peripheral Pain
Keywords: Nerve Conduction Studies
Nerve damage
Transradial angiography
Lead sponsor: Bursa City Hospital
Sponsor class: OTHER_GOV
First posted: 2025-04-13
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: So far, apart from a limited number of case reports and small-scale studies, the frequency and severity of this complication have not been objectively evaluated using electromyography (EMG). In this study, presence, severity, and extent of nerve injury (one of the potential complications following the transradial approach (TRA)) were evaluated by EMG studies in patients managed at Bursa City Hospital.

Detailed description: Evaluation of peripheral nerve injury after transradial angiography with nerve conduction studies.

Eligibility criteria: Inclusion Criteria:

20-60 years old patiens who applied trans angiograhy were included to study

Exclusion Criteria:

* Having cognitive disorders
* Patients who have story of cardiac pace / ICD,
* History of polyneuropathy,
* Previous nerve damages,
* Deformities on arm,
* Plexopathy,
* Radiculopathy,
* Spinal surgery.
* Having medical treatment for any kind of neuropathy
* Having Cognitive disorders

Primary outcomes:
measure: Nerve conduction studies (NCS)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03949556: INternet-based Programmes FOR the Prevention of Suicidal Ideation in MEDical Students
Official title: Internet-based Programmes for the Prevention of Suicidal Ideation in Medical Students
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Suicidal Ideation
Lead sponsor: Centre Hospitalier Charles Perrens, Bordeaux
Sponsor class: OTHER_GOV
First posted: 2019-05-14
Enrollment: 2544
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: An open three-arm randomized controlled trial will be conducted to assess the effectiveness of two programmes of suicide prevention in fourth-year medical students and first-year interns; one based on stress management using cognitive and behavioural principles and the other on health promotion. Their respective effectiveness will be compared with a control condition. Participants will be assessed using validated questionnaires online at inclusion (before intervention) and at 6 (end of the intervention), 12, and 18 months.
Primary purpose: PREVENTION

Brief summary: Two programmes have been built to prevent suicidal ideation; one focuses on stress management based on cognitive and behavioural principles and the other on health promotion.

Detailed description: The main objective will be assessing their respective effectiveness on suicidal ideation (at least one occurrence over a 12-month period after the end of the intervention), through a randomized controlled trial, in medical students and interns.

Eligibility criteria: Inclusion Criteria:

* Being registered in the fourth year of medical studies or in the first year of residency (internship), as they appear as two critical periods over medical studies
* Being registered in the i-Share cohort
* 18 year-old and over
* Speaking and reading French
* Having given an informed consent
* Ability to understand the type, the aims and the methodology of the study
* Agreement for online clinical assessment
* Having a mobile phone number and an e-mail address
* To be beneficiary of a health insurance programme

Exclusion Criteria:

* Refusing to participate
* Protective supervision: curatorship, guardianship

Primary outcomes:
measure: Suicidal ideation observed at least at one of the three assessment contacts (6, 12, 18 months).
timeFrame: 18 months
Secondary outcomes:
measure: Suicidal behaviour identified at least once after the intervention.
timeFrame: 18 months
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Centre Hospitalier Charles PERRENS
Study officials:
affiliation: Centre Hospitalier CHARLES PERRENS
name: MARIE TOURNIER, MD, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03008356: L-carnitine for Fatigue in COPD
Official title: L-Carnitine Supplementation With and Without Health Coaching for Fatigue in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Copd
Fatigue
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2017-01-02
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: supplementation with L-carnitine that is available both as an FDA-approved therapy for primary carnitine deficiency, as well as widely available as an over-the-counter ergogenic aid will improve wellbeing and function measured by questionnaires in patient with chronic obstructive pulmonary disease (COPD).

based on our review of literature that addition of health coaching (HC) to L-carnitine will yield greater gains.


Eligibility criteria: Inclusion criteria:

- COPD patients with a positive screen for fatigue

Exclusion criteria:

* Vulnerable population - pregnant women, prisoners, unable to provide consent
* Pre-menopausal/breastfeeding women (pregnancy category B)
* Thyroid disease
* Anticoagulation therapy
* Decompensated cardiac disease
* Chronic Kidney Disease (CKD4 or above)
* Known seizure disorder
* Active malignancy
* Exacerbation of underlying pulmonary disease or acute illness in the 6 weeks before screening
* Enrollment in the past 6 weeks or currently in a cardiac or pulmonary rehab program or other physical fitness class(es).
* Difficulty with swallowing pills

Primary outcomes:
measure: Change in Exercise Capacity as Measured by the Six Minute Walk Test (6MWT)
timeFrame: baseline, end of 8 week intervention
Secondary outcomes:
measure: Change in Health-Related Quality of Life as Measured by the Chronic Respiratory Questionnaire (CRQ)
timeFrame: baseline, end of 8 week intervention
measure: Change in Physical Fatigue as Measured by the Chalder Fatigue Questionnaire (CFQ-11)
timeFrame: baseline, end of 8 week intervention
measure: Physical Activity as Measured by the SenseWear Armband
timeFrame: end of 8 week intervention
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Roberto P Benzo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03404856: Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14
Official title: Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Glycogen Storage Disease, Type 14
Keywords: CDG It; CDGIt PHOSPHOGLUCOMUTASE 1 DEFICIENCY PGM1 DEFICIENCY GLYCOGEN STORAGE DISEASE XIV; GSD14 GSD XIV
Lead sponsor: Orpha Labs
Sponsor class: INDUSTRY
First posted: 2018-01-19
Enrollment: 5
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study of ORL-1G in Patients With Glycogen Storage Disease Type 14


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Glycogen Storage Disease Type 14.
* Less than 18 years old.

Exclusion Criteria:

* Diagnosis of any other disease that is not a manifestation of Glycogen Storage Disease Type 14.

Primary outcomes:
measure: Improvement in liver function.
timeFrame: 3 months after treatment starts
Secondary outcomes:
measure: Improvement in serum transferrin glycosylation pattern.
timeFrame: 30 days after treatment starts
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Orpha Labs
Study officials:
References:
Clinical trial NCT01748656: Target Volume in Noninvasive Positive Pressure Ventilation
Official title: Comparison of Two Noninvasive Positive Pressure Ventilation Devices Using Target Volume Modes in Obesity Hypoventilation Syndrome (OHS): A Pilot Randomized Crossover Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity Hypoventilation Syndrome
Keywords: Noninvasive ventilation
Obesity Hypoventilation Syndrome
Lead sponsor: AGIR à Dom
Sponsor class: OTHER
Collaborators: name: ResMed
First posted: 2012-12-12
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Patients with OHS are efficiently managed with long term home-based nocturnal noninvasive positive pressure ventilation (NIPPV). Several NIPPV devices offer the feature of automatically adjusting pressure support (and/or respiratory back-up rate) on the basis of a pre-determined "ideal tidal volume" or "ideal ventilation". However algorithms used to achieve these ideal targets are different among different commercialized devices and the relative efficacy from an algorithm compared to another remains unknown. The main objective is this study is to compare two commercialized NIPPV that have this option

Detailed description: RESMED Stellar-150 (IVAPS mode)versus PHILIPS-RESPIRONICS A30 (AVAPS-mode).

Eligibility criteria: Inclusion Criteria:

* Patient with Obesity hypoventilation Syndrome (BMI≥ 30 kg/m2 and diurnal PaCO2 ≥ 45mmHg at diagnosis after exclusion of others causes of hypoventilation)
* 18 to 75 years old
* In stable state but treated by nocturnal NIPPV for more than 3 months and adherent to NIPPV (above 4h/night).

Exclusion Criteria:

* patient treated with additional long term Oxygen therapy
* Patient previously treated by AVAPS mode or IVAPS mode

Primary outcomes:
measure: Mean Nocturnal transcutaneous CO2 pressure (Mean nocturnal PtCO2)
timeFrame: 1 night
Secondary outcomes:
measure: Mean transcutaneous CO2 pressure during REM Sleep
timeFrame: 1 Night
measure: Mean nocturnal SpO2
timeFrame: 1 night
measure: Awake arterial PaCO2 after 1 hour of NIPPV withdrawal
timeFrame: After 1 night
measure: Micro-arousals/hour of sleep
timeFrame: 1 night
measure: Sleep Quality assess by Visual analogic scale (100mm)
timeFrame: 1 night
measure: Respiratory residual events detected by NIPPV built-in softwares
timeFrame: 1 Night
Other outcomes:
Locations:
city: Grenoble
country: France
facility: Sleep Laboratory, Grenoble Univeristy Hospital
Study officials:
affiliation: CHU Grenoble France
name: Jean Louis Pepin, MD PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01643356: Interventions to Reduce Excess Weight Gain in Pregnancy
Official title: Interventions to Reduce Excess Weight Gain in Pregnancy in Overweight and Obese Mothers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Pregnancy
Keywords: weight
pregnancy
behavioral intervention
obesity
Lead sponsor: Tufts University
Sponsor class: OTHER
First posted: 2012-07-18
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study will use a comprehensive behavioral intervention adapted for pregnant women to change dietary intake, eating behavior and physical activity. The central hypothesis of this study is that the intervention will reduce excess gestational weight gain and achieve clinical and metabolic benefits in obese and overweight pregnant women and their infants over the first year of life.


Eligibility criteria: Inclusion Criteria:

* Age 18-45 years
* In first trimester of pregnancy
* Must be willing to not join any other weight control program while in the study
* BMI of 25-40 kg/m2
* Willingness and ability to attend support group meetings either in person or via web
* Must be able to read, speak, and understand English

Exclusion Criteria:

* Carrying multiple fetuses
* Gestational diabetes mellitus at study entry
* Type 2 diabetes mellitus or blood glucose \>125 mg/dl at screening
* Self reported current substance abuse
* Current smoking
* Alchol consumption of more than 1 drink per day
* Preexisting medical conditions (includes bariatric surgery) or use of medications that would impact study involvement or outcomes testing
* Eating disorder in the past 2 years
* Depression or diagnosis of bipolar disorder
* Concurrent participation in any other research study that would impact participation in this investigation

Primary outcomes:
measure: Maternal and Infant Body Weight Change
timeFrame: From first trimester through 1 year post-partum
Secondary outcomes:
measure: Infant Outcomes
timeFrame: From birth through first year
measure: Maternal and Perinatal Outcomes
timeFrame: First trimester through 1 year post-partum
Other outcomes:
Locations:
city: Boston
country: United States
facility: Tufts Medical Center
state: Massachusetts
city: Boston
country: United States
facility: Tufts University Human Nutrition Research Center on Aging
state: Massachusetts
Study officials:
affiliation: Tufts University
name: Susan B Roberts, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00882856: Treating Clozapine-induced Sinustachycardia With Bisoprolol
Official title: Treating Clozapine-induced Sinustachycardia With Bisoprolol - a Double Blinded Placebo Controlled Cross Over Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Clozapine-induced Sinustachycardia
Keywords: Clozapine
Sinustachycardia
Heartrate variability
Cardiomyopathy
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aalborg University Hospital
name: Aalborg University
First posted: 2009-04-17
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Clozapine-induced sinustachycardia occurs in 25% of patients treated with clozapine and sustained sinustachycardia might be a risk factor for dilated cardiomyopathy. This double-blinded cross over placebo controlled study investigate whether 10 mg bisoprolol are efficient in treating clozapine-induced sinustachycardia measured as heart rate, heart rate variability, QTc and T-wave morphology.


Eligibility criteria: Inclusion Criteria:

* Treated with clozapine \> 3 months and minimum 100 mg/day
* Fixed dose 14 days before inclusion
* Heart rate \> 100 (ECG)
* Pregnancy test negative
* Clozapine-induced sinustachycardia documented by ECG or case record
* Sexual abstinence or contraception
* Informed consent

Exclusion Criteria:

* Substance abuse
* Physical diseases, contraindications for clozapine or bisoprolol
* Asthma or chronic obstructive lung disease
* Blood pressure \< 100/60 or recent history of syncopes
* QTc\>500 ms, SA-block, AV- block II or III
* Restrictions by Danish mental act
* Allergic to clozapine or bisoprolol

Primary outcomes:
measure: Heart rate variability
timeFrame: Baseline, visit 1+2+3
Secondary outcomes:
measure: QTc, T-wave morphology and other ECG markers
timeFrame: Baseline, visit 1+2+3
measure: Hamilton-Anxiety scale
timeFrame: Baseline, visit 1+2+3
measure: Salivation rate
timeFrame: Baseline, visit 1+2+3
measure: Orthostatic blood pressure
timeFrame: Baseline, visit 1+2+3
measure: WHO-QoL
timeFrame: Baseline, visit 1+2+3
measure: Nocturnal Hypersalivation Rating Scale (NHRS).
timeFrame: Baseline, visit 1+2+3
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg University Hospital, Psychiatry
Study officials:
affiliation: Aalborg University Hospital
name: Ole Schjerning, M.D.
role: STUDY_DIRECTOR
References: